Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager (Gammabody™), in relapsed/refractory hematological malignancies June 5, 2022June 4, 2022 2022 American Society of Clinical Oncology (ASCO) Annual Meeting presentation Brojil, et al.